Oncogenic micro-RNAs and Renal Cell Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Tumorigenesis involves complex cellular interactions and epigenetic alterations affecting microRNA (miRNA) expression.
• OncomiRs, miRNAs with aberrant expression in tumors, are crucial in tumorigenesis, often showing down-regulation.
• Renal cell carcinoma (RCC) exhibits altered signaling pathways, with miRNAs potentially targeting key molecules like HIF, VEGF, and mTOR.

Purpose of the Study:

• To investigate the role of miRNAs and cancer stem cells (CSCs) in renal cell carcinoma (RCC) progression.
• To explore the potential of miRNA signatures as biomarkers for RCC diagnosis and treatment.

Main Methods:

• Analysis of miRNA expression patterns in tumor cells, focusing on oncomiRs.
• Characterization of cancer stem cell (CSC) populations in RCC, including marker expression (CD105) and functional properties (self-renewal, clonogenicity).
• Correlation of CSC phenotype with epithelial-mesenchymal transition (EMT) and miRNA expression profiles.

Main Results:

• CSCs in RCC express CD105 and possess self-renewal and tumor-generating capabilities.
• The CSC phenotype is associated with specific miRNA expression patterns, including down-regulation of anti-tumor miRNAs.
• Circulating miRNA patterns can differentiate between healthy individuals and RCC patients.

Conclusions:

• miRNA dysregulation, especially in CSCs, is integral to RCC development and progression.
• miRNA signatures hold significant potential as diagnostic and prognostic biomarkers for RCC.
• miRNA profiling may guide therapeutic strategies and predict relapse or metastasis risk in RCC patients.